{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:13:03Z","timestamp":1783523583179,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s10557-024-07646-1","type":"journal-article","created":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T03:14:25Z","timestamp":1731294865000},"page":"1343-1352","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Associations of SGLT2i with Cardiorenal Outcomes Among Diabetics with Prostate Cancer on Hormone Therapy"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6757-6480","authenticated-orcid":false,"given":"Efstratios","family":"Koutroumpakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rushin","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumanth","family":"Khadke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aram","family":"Bedrosian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixin","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Connell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagriti","family":"Upadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sourbha S.","family":"Dani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew W.","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Logothetis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadeer","family":"Al-Kindi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anju","family":"Nohria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarju","family":"Ganatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Deswal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,11]]},"reference":[{"issue":"1","key":"7646_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"7646_CR2","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/pcan.2011.55","volume":"15","author":"S Shikanov","year":"2012","unstructured":"Shikanov S, Kocherginsky M, Shalhav AL, Eggener SE. Cause-specific mortality following radical prostatectomy. Prostate Cancer Prostatic Dis. 2012;15(1):106\u201310.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"7646_CR3","first-page":"33","volume":"9","author":"AW Hahn","year":"2023","unstructured":"Hahn AW, Thoman W, Koutroumpakis E, et al. Cardiometabolic healthcare for men with prostate cancer: an MD Anderson Cancer Center experience. Cardiooncology. 2023;9(1):33.","journal-title":"Cardiooncology"},{"issue":"6","key":"7646_CR4","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1097\/JU.0000000000000714","volume":"203","author":"DP Leong","year":"2020","unstructured":"Leong DP, Fradet V, Shayegan B, et al. Cardiovascular risk in men with prostate cancer: insights from the RADICAL PC study. J Urol. 2020;203(6):1109\u201316.","journal-title":"J Urol"},{"issue":"3","key":"7646_CR5","doi-asserted-by":"publisher","DOI":"10.1161\/HCG.0000000000000082","volume":"14","author":"TM Okwuosa","year":"2021","unstructured":"Okwuosa TM, Morgans A, Rhee JW, et al. Impact of hormonal therapies for treatment of hormone-dependent cancers (breast and prostate) on the cardiovascular system: effects and modifications: a scientific statement from the American Heart Association. Circ Genom Precis Med. 2021;14(3): e000082.","journal-title":"Circ Genom Precis Med"},{"issue":"27","key":"7646_CR6","doi-asserted-by":"publisher","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","volume":"24","author":"NL Keating","year":"2006","unstructured":"Keating NL, O\u2019Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24(27):4448\u201356.","journal-title":"J Clin Oncol"},{"issue":"2","key":"7646_CR7","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.0070","volume":"4","author":"L Sun","year":"2021","unstructured":"Sun L, Parikh RB, Hubbard RA, et al. Assessment and management of cardiovascular risk factors among US veterans with prostate cancer. JAMA Netw Open. 2021;4(2): e210070.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"7646_CR8","first-page":"S140","volume":"46","author":"NA ElSayed","year":"2022","unstructured":"ElSayed NA, Aleppo G, Aroda VR, et al. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes\u20142023. Diabetes Care. 2022;46(1):S140\u201357.","journal-title":"Diabetes Care"},{"issue":"7","key":"7646_CR9","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"24","key":"7646_CR10","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306.","journal-title":"N Engl J Med"},{"issue":"4","key":"7646_CR11","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2018","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2018;380(4):347\u201357.","journal-title":"N Engl J Med"},{"issue":"22","key":"7646_CR12","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"key":"7646_CR13","unstructured":"https:\/\/trinetx.com\/. Accessed on Oct 1, 2023."},{"key":"7646_CR14","unstructured":"FDA approves invokana to treat type 2 diabetes. http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm345848.htm. Date: March 29, 2013."},{"issue":"9896","key":"7646_CR15","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/S0140-6736(13)60902-2","volume":"382","author":"M Diamant","year":"2013","unstructured":"Diamant M, Morsink LM. SGLT2 inhibitors for diabetes: turning symptoms into therapy. Lancet. 2013;382(9896):917\u20138.","journal-title":"Lancet"},{"issue":"4","key":"7646_CR16","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","volume":"167","author":"TJ VanderWeele","year":"2017","unstructured":"VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med. 2017;167(4):268\u201374.","journal-title":"Ann Intern Med"},{"issue":"2","key":"7646_CR17","doi-asserted-by":"publisher","first-page":"e210070","DOI":"10.1001\/jamanetworkopen.2021.0070","volume":"4","author":"L Sun","year":"2021","unstructured":"Sun L, Parikh RB, Hubbard RA, et al. Assessment and management of cardiovascular risk factors among US veterans with prostate cancer. JAMA Netw Open. 2021;4(2):e210070\u2013e210070.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"7646_CR18","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jaccao.2023.01.001","volume":"5","author":"S Moningi","year":"2023","unstructured":"Moningi S, Nguyen PL. Uncontrolled cardiovascular risk factors in prostate cancer patients: are we leaving too much on the table? JACC CardioOncol. 2023;5(1):82\u20134.","journal-title":"JACC CardioOncol"},{"key":"7646_CR19","unstructured":"https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-jardiance-reduce-cardiovascular-death-adults-type-2-diabetes. Accessed on: Oct 23. 2023."},{"key":"7646_CR20","unstructured":"https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-treatment-type-heart-failure. Accessed on  Oct 23, 2023."},{"key":"7646_CR21","unstructured":"https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-treatment-chronic-kidney-disease. Accessed on  Oct 23, 2023."},{"key":"7646_CR22","unstructured":"https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-treatment-wider-range-patients-heart-failure. Accessed on Oct 23, 2023."},{"issue":"17","key":"7646_CR23","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.022222","volume":"10","author":"AK Pandey","year":"2021","unstructured":"Pandey AK, Okaj I, Kaur H, et al. Sodium-glucose co-transporter inhibitors and atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2021;10(17): e022222.","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"7646_CR24","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","volume":"5","author":"GD Lopaschuk","year":"2020","unstructured":"Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review. JACC Basic Transl Sci. 2020;5(6):632\u201344.","journal-title":"JACC Basic Transl Sci"},{"issue":"3","key":"7646_CR25","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.amjmed.2019.08.035","volume":"133","author":"E Koutroumpakis","year":"2020","unstructured":"Koutroumpakis E, Jozwik B, Aguilar D, Taegtmeyer H. Strategies of unloading the failing heart from metabolic stress. Am J Med. 2020;133(3):290\u20136.","journal-title":"Am J Med"},{"key":"7646_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.eururo.2023.04.015","volume":"85","author":"CJ Logothetis","year":"2023","unstructured":"Logothetis CJ, Hahn AW. Challenging the prevailing therapeutic dogma for prostate cancer: the case for an overlap syndrome. Eur Urol. 2023;85:3.","journal-title":"Eur Urol"},{"issue":"30","key":"7646_CR27","doi-asserted-by":"publisher","first-page":"E4111","DOI":"10.1073\/pnas.1511698112","volume":"112","author":"C Scafoglio","year":"2015","unstructured":"Scafoglio C, Hirayama BA, Kepe V, et al. Functional expression of sodium-glucose transporters in cancer. Proc Natl Acad Sci U S A. 2015;112(30):E4111-4119.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"7646_CR28","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/s42003-023-05289-w","volume":"6","author":"A Ali","year":"2023","unstructured":"Ali A, Mekhaeil B, Biziotis OD, et al. The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy. Commun Biol. 2023;6(1):919.","journal-title":"Commun Biol"},{"issue":"16","key":"7646_CR29","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1161\/CIRCULATIONAHA.121.056810","volume":"144","author":"RD Lopes","year":"2021","unstructured":"Lopes RD, Higano CS, Slovin SF, et al. Cardiovascular safety of degarelix versus leuprolide in patients with prostate cancer: the primary results of the PRONOUNCE randomized trial. Circulation. 2021;144(16):1295\u2013307.","journal-title":"Circulation"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-024-07646-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-024-07646-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-024-07646-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T07:01:19Z","timestamp":1766127679000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-024-07646-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,11]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["7646"],"URL":"https:\/\/doi.org\/10.1007\/s10557-024-07646-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4510870\/v1","asserted-by":"object"}]},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,11]]},"assertion":[{"value":"2 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is an observational study. The need for Institutional Review Board (IRB) approval was waived by Lahey Clinic IRB due to the use of deidentified data for the analysis. The study findings are reported per the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines for cohort studies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"EK is supported in part by NIH\/NCI 1RO1HL157273 and by CPRIT RP200381. AD is supported in part by the Ting Tsung and Wei Fong Chao Distinguished Chair and is a consultant for Bayer. JB is consultant for Abbott, American Regent, Amgen, Applied Therapeutic, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardiac Dimension, Cardior, CVRx, Cytokinetics, Edwards, Element Science, Innolife, Impulse Dynamics, Imbria, Inventiva, Lexicon, Lilly, LivaNova, Janssen, Medtronics, Merck, Occlutech, Novartis, Novo Nordisk, Pfizer, Pharmacosmos, Pharmain, Roche, Sequana, SQ Innovation, and Vifor. AWH is consultant for Janssen, Intellisphere, Exelixis, has received honoraria from Medscape, Binaytara Foundation, travel support from Dava Oncology, and institutional funding from Bayer and Eisai. The remaining authors have nothing to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}